{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:28:15Z","timestamp":1792985295005,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002721","name":"Charcot-Marie-Tooth Association","doi-asserted-by":"publisher","award":["2019-21"],"award-info":[{"award-number":["2019-21"]}],"id":[{"id":"10.13039\/100002721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ymthe.2023.08.020","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T01:57:42Z","timestamp":1693187862000},"page":"3290-3307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4207-7973","authenticated-orcid":false,"given":"Elena","family":"Georgiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Kagiava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Sargiannidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Schiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Stavrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Tryfonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-8094","authenticated-orcid":false,"given":"Kleopas A.","family":"Kleopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.08.020_bib1","series-title":"GeneReviews","article-title":"SH3TC2-Related Hereditary Motor and Sensory Neuropathy","author":"Azzedine","year":"1993"},{"key":"10.1016\/j.ymthe.2023.08.020_bib2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/jnnp-2014-308826","article-title":"CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis","volume":"86","author":"Fridman","year":"2015","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2023.08.020_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/jns.12175","article-title":"Screening for SH3TC2 gene mutations in a series of demyelinating recessive Charcot-Marie-Tooth disease (CMT4)","volume":"21","author":"Piscosquito","year":"2016","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"key":"10.1016\/j.ymthe.2023.08.020_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jnc.14217","article-title":"Frequent genes in rare diseases: panel-based next generation sequencing to disclose causal mutations in hereditary neuropathies","volume":"143","author":"Dohrn","year":"2017","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2023.08.020_bib5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1212\/WNL.48.4.867","article-title":"A clinical, electrophysiologic, neuropathologic, and genetic study of two large Algerian families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease","volume":"48","author":"Kessali","year":"1997","journal-title":"Neurol. Apr"},{"key":"10.1016\/j.ymthe.2023.08.020_bib6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/jnnp.66.5.569","article-title":"Study on the gene and phenotypic characterisation of autosomal recessive demyelinating motor and sensory neuropathy (Charcot-Marie-Tooth disease) with a gene locus on chromosome 5q23-q33","volume":"66","author":"Gabre\u00ebls-Festen","year":"1999","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2023.08.020_bib7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1212\/01.wnl.0000230225.19797.93","article-title":"Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations","volume":"67","author":"Azzedine","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2023.08.020_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jns.12305","article-title":"Mutational screening of the SH3TC2 gene in Greek patients with suspected demyelinating recessive Charcot-Marie-Tooth disease reveals a varied and unusual phenotypic spectrum","volume":"24","author":"Kontogeorgiou","year":"2019","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"key":"10.1016\/j.ymthe.2023.08.020_bib9","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1136\/jmg.2005.034132","article-title":"A novel Gypsy founder mutation, p.Arg1109X in the CMT4C gene, causes variable peripheral neuropathy phenotypes","volume":"42","author":"Gooding","year":"2005","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.ymthe.2023.08.020_bib10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.nmd.2006.05.005","article-title":"Clinical spectrum of CMT4C disease in patients homozygous for the p.Arg1109X mutation in SH3TC2","volume":"16","author":"Colomer","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2023.08.020_bib11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/mus.24640","article-title":"Phenotypic variability of CMT4C in a French-Canadian kindred","volume":"52","author":"Varley","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2023.08.020_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1086\/379525","article-title":"Mutations in a gene encoding a novel SH3\/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy","volume":"73","author":"Senderek","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2023.08.020_bib13","doi-asserted-by":"crossref","first-page":"17528","DOI":"10.1073\/pnas.0905523106","article-title":"SH3TC2\/KIAA1985 protein is required for proper myelination and the integrity of the node of Ranvier in the peripheral nervous system","volume":"106","author":"Arnaud","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.020_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1399-0004.2011.01640.x","article-title":"High frequency of SH3TC2 mutations in Czech HMSN I patients","volume":"80","author":"La\u0161\u0161uthov\u00e1","year":"2011","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymthe.2023.08.020_bib15","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1093\/hmg\/ddp427","article-title":"Missense mutations in the SH3TC2 protein causing Charcot-Marie-Tooth disease type 4C affect its localization in the plasma membrane and endocytic pathway","volume":"18","author":"Lupo","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2023.08.020_bib16","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/glia.22493","article-title":"Sh3tc2 deficiency affects neuregulin-1\/ErbB signaling","volume":"61","author":"Gouttenoire","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.ymthe.2023.08.020_bib17","first-page":"730","article-title":"Axons and myelinating glia: An intimate contact","volume":"63","author":"Zoupi","year":"2011","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ymthe.2023.08.020_bib18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/brain\/awz064","article-title":"Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy","volume":"142","author":"Schiza","year":"2019","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2023.08.020_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2023.08.020_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2015.00036","article-title":"Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice","volume":"8","author":"Tanguy","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2023.08.020_bib21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/mt.2015.189","article-title":"Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII","volume":"24","author":"Gurda","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.020_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41434-021-00250-0","article-title":"AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy","volume":"28","author":"Kagiava","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2023.08.020_bib23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/hum.2017.151","article-title":"AAVrh10 Gene Therapy Ameliorates Central and Peripheral Nervous System Disease in Canine Globoid Cell Leukodystrophy (Krabbe Disease)","volume":"29","author":"Bradbury","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.08.020_bib24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral Immune Response to AAV","volume":"4","author":"Calcedo","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2023.08.020_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/sj.mt.6300394","article-title":"Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells","volume":"16","author":"Hargrove","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.020_bib26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.ymthe.2023.08.020_bib27","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2023.08.020_bib28","doi-asserted-by":"crossref","first-page":"e159814","DOI":"10.1172\/JCI159814","article-title":"A translatable RNAi-driven gene therapy silences PMP22\/Pmp22 genes and improves neuropathy in CMT1A mice","volume":"132","author":"Stavrou","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2023.08.020_bib29","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1523\/JNEUROSCI.3082-04.2005","article-title":"Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice","volume":"25","author":"Scherer","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2023.08.020_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.24441","article-title":"Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease","volume":"78","author":"Sargiannidou","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2023.08.020_bib31","doi-asserted-by":"crossref","first-page":"20111","DOI":"10.1074\/jbc.M109.022426","article-title":"Induction of myelin protein zero by early growth response 2 through upstream and intragenic elements","volume":"284","author":"Jang","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2023.08.020_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02694-1","article-title":"Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery","volume":"11","author":"Kagiava","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.08.020_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137431","article-title":"The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in the Tumor Microenvironment","volume":"23","author":"Greenshpan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2023.08.020_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0042-6822(03)00162-4","article-title":"Differential transgene expression in brain cells in\u00a0vivo and in\u00a0vitro from AAV-2 vectors with small transcriptional control units","volume":"311","author":"K\u00fcgler","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2023.08.020_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1113\/expphysiol.2004.028159","article-title":"Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in\u00a0vitro and in\u00a0vivo","volume":"90","author":"Shevtsova","year":"2005","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.ymthe.2023.08.020_bib36","doi-asserted-by":"crossref","first-page":"E2421","DOI":"10.1073\/pnas.1522202113","article-title":"Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy","volume":"113","author":"Kagiava","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.020_bib37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nature13800","article-title":"A three-dimensional human neural cell culture model of Alzheimer's disease","volume":"515","author":"Choi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.08.020_bib38","first-page":"599","article-title":"Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model","volume":"140","author":"Georgiou","year":"2017","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2023.08.020_bib39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","article-title":"AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy","volume":"26","author":"Pattali","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2023.08.020_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs."},{"key":"10.1016\/j.ymthe.2023.08.020_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2023.08.020_bib42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbrc.2011.11.121","article-title":"Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy","volume":"417","author":"Glascock","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2023.08.020_bib43","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/mt.2012.153","article-title":"Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease","volume":"20","author":"Rafi","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.020_bib44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41591-019-0674-1","article-title":"Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS","volume":"26","author":"Bravo-Hernandez","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.08.020_bib45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.24332","article-title":"A large animal model of spinal muscular atrophy and correction of phenotype","volume":"77","author":"Duque","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2023.08.020_bib46","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.020_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90807","article-title":"Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease","volume":"2","author":"Gessler","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2023.08.020_bib48","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/mt.2011.157","article-title":"Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders","volume":"19","author":"Bevan","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.020_bib49","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1038\/s41467-021-22593-3","article-title":"AAV2\/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A","volume":"12","author":"Gautier","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.08.020_bib50","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/hmg\/ddy056","article-title":"Intrathecal gene therapy in mouse models expressing CMT1X mutations","volume":"27","author":"Kagiava","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2023.08.020_bib51","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.23329","article-title":"Node of Ranvier length as a potential regulator of myelinated axon conduction speed","volume":"6","author":"Arancibia-Carcamo","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2023.08.020_bib52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.neuron.2010.02.004","article-title":"A glial signal consisting of gliomedin and NrCAM clusters axonal Na+ channels during the formation of nodes of Ranvier","volume":"65","author":"Feinberg","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2023.08.020_bib53","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/imm.12233","article-title":"Inflammation in neurodegenerative diseases--an update","volume":"142","author":"Amor","year":"2014","journal-title":"Immunology"},{"issue":"Pt 8","key":"10.1016\/j.ymthe.2023.08.020_bib54","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1093\/brain\/awq168","article-title":"SH3TC2, a protein mutant in Charcot-Marie-Tooth neuropathy, links peripheral nerve myelination to endosomal recycling","volume":"133","author":"Stendel","year":"2010","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2023.08.020_bib55","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/hmg\/ddp565","article-title":"Mistargeting of SH3TC2 away from the recycling endosome causes Charcot-Marie-Tooth disease type 4C","volume":"19","author":"Roberts","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"3 Pt 1","key":"10.1016\/j.ymthe.2023.08.020_bib56","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1523\/JNEUROSCI.15-03-01797.1995","article-title":"Polarization of myelinating Schwann cell surface membranes: role of microtubules and the trans-Golgi network","volume":"15","author":"Trapp","year":"1995","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2023.08.020_bib57","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1523\/JNEUROSCI.16-03-00946.1996","article-title":"Axons regulate the distribution of Schwann cell microtubules","volume":"16","author":"Kidd","year":"1996","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2023.08.020_bib58","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ncb917","article-title":"Three-dimensional analysis of post-Golgi carrier exocytosis in epithelial cells","volume":"5","author":"Kreitzer","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ymthe.2023.08.020_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19124072","article-title":"Neuromuscular Junction Changes in a Mouse Model of Charcot-Marie-Tooth Disease Type 4C","volume":"19","author":"Cipriani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2023.08.020_bib60","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jns.12477","article-title":"A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-Tooth disease","volume":"27","author":"Rossor","year":"2022","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"key":"10.1016\/j.ymthe.2023.08.020_bib61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1472-6750-6-34","article-title":"Comparison of lentiviral vector titration methods","volume":"6","author":"Geraerts","year":"2006","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.ymthe.2023.08.020_bib62","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-4939-7862-5_22","article-title":"Intrathecal Delivery of Viral Vectors for Gene Therapy","volume":"1791","author":"Kagiava","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2023.08.020_bib63","first-page":"e518","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies","volume":"90","author":"Sandelius","year":"2018","journal-title":"Neurol. Feb 6"},{"key":"10.1016\/j.ymthe.2023.08.020_bib64","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","article-title":"Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia","volume":"87","author":"Rohrer","year":"2016","journal-title":"Neurology"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623004525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623004525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:45:53Z","timestamp":1777617953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623004525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1525001623004525"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}]}}